Setterwalls has advised SynAct Pharma AB in connection with a fully guaranteed rights issue of approximately SEK 150 million

Setterwalls has advised SynAct Pharma AB (”SynAct”) in connection with a fully guaranteed rights issue of approximately SEK 150 million before issue costs.

SynAct Pharma conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. The proceeds from the issue will be used to conduct additional clinical phase 2 development with the drug candidate AP1189 in rheumatoid arthritis, continued development of AP1189 for kidney disease, conduct other research and development activities related to AP1189 and new molecules as well as to cover general administration costs. SynAct Pharma is listed on Spotlight Stock Market (ticker: SYNACT).